Spots Global Cancer Trial Database for Analysis of miRNA Expression in Endometrial Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Analysis of miRNA Expression in Endometrial Cancer
Official Title: Identification of miRNAs in Endometrial Cancer as Novel Diagnostic and Prognostic Biomarkers
Study ID: NCT04845425
Conditions
Interventions
Study Description
Brief Summary: The TCGA project identified four distinct prognostic groups of endometrial carcinoma (EC) based on molecular alterations: (i) the ultramutated subtype that encompasses POLE mutated (POLE) cases; (ii) the hypermutated subtype, characterized by MisMatch Repair deficiency (MMRd); (iii) the copy-number high subtype, with p53 abnormal/mutated features (p53abn); (iv) the copy-number low subtype, known as No Specific Molecular Profile (NSMP). Although the prognostic value of TCGA molecular classification, NSMP carcinomas present a wide variability in molecular alterations and biological aggressiveness. Given that the study aims to evaluate the miRNA expression profile to identify novel potential biomarkers to better stratify the EC patients, taking into account the molecular status
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
IRCCS- Azienda Ospedaliera-Universitaria di Bologna, Bologna, Bo, Italy
Contact Details
Name: Anna Myriam Perrone
Affiliation: IRCCS- Azienda Ospedaliera-Universitaria di Bologna
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
